- Home
- BLFS vs XERS Comparison
BLFS vs XERS Comparison
Compare BLFS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- XERS
- Stock Information
- Founded
- BLFS 1987
- XERS 2005
- Country
- BLFS United States
- XERS United States
- Employees
- BLFS N/A
- XERS N/A
- Industry
- BLFS Medical/Dental Instruments
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- XERS Health Care
- Exchange
- BLFS Nasdaq
- XERS Nasdaq
- Market Cap
- BLFS 1.3B
- XERS 1.3B
- IPO Year
- BLFS 1989
- XERS 2018
- Fundamental
- Price
- BLFS $24.10
- XERS $7.32
- Analyst Decision
- BLFS Strong Buy
- XERS Strong Buy
- Analyst Count
- BLFS 5
- XERS 7
- Target Price
- BLFS $30.60
- XERS $9.43
- AVG Volume (30 Days)
- BLFS 327.5K
- XERS 2.9M
- Earning Date
- BLFS 11-06-2025
- XERS 11-06-2025
- Dividend Yield
- BLFS N/A
- XERS N/A
- EPS Growth
- BLFS N/A
- XERS N/A
- EPS
- BLFS N/A
- XERS N/A
- Revenue
- BLFS $100,144,000.00
- XERS $266,137,000.00
- Revenue This Year
- BLFS $25.65
- XERS $43.89
- Revenue Next Year
- BLFS $14.81
- XERS $20.40
- P/E Ratio
- BLFS N/A
- XERS N/A
- Revenue Growth
- BLFS 87.53
- XERS 42.05
- 52 Week Low
- BLFS $19.10
- XERS $2.82
- 52 Week High
- BLFS $29.62
- XERS $10.08
- Technical
- Relative Strength Index (RSI)
- BLFS 33.03
- XERS 34.19
- Support Level
- BLFS $25.49
- XERS $7.01
- Resistance Level
- BLFS $28.21
- XERS $7.86
- Average True Range (ATR)
- BLFS 1.00
- XERS 0.57
- MACD
- BLFS -0.44
- XERS -0.26
- Stochastic Oscillator
- BLFS 8.19
- XERS 9.58
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).